Simon Vyse
Institute of Cancer Research · 26 works · 1,622 citations · h-index 16
Top works
- Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
- Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
- UBE2L3 Polymorphism Amplifies NF-κB Activation and Promotes Plasma Cell Development, Linking Linear Ubiquitination to Multiple Autoimmune Diseases
- Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer
- Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors
- Three‐dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model
- De novo mutations implicate novel genes in systemic lupus erythematosus
- Exploiting receptor tyrosine kinase co-activation for cancer therapy
- Next-generation sequencing for the management of sarcomas with no known driver mutations
- Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer
- Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1
- Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib
- Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
- Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
- Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer
- Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus
- Advances in mass spectrometry based strategies to study receptor tyrosine kinases
- 205 Correlation of Soluble Vascular Cell Adhesion Molecule 1 with B Cell Activation and Plasma Cells in Systemic Lupus Erythematosus
- O37. The Autoimmune Risk Gene UBE2L3 is Highly Expressed During B Cell Proliferation and is Correlated with Plasmablast and Plasma Cell Expansion in SLE
- Dual Targeting of PDGFR alpha and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors